Key TakeawaysRaymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform."The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women.Lenacapavir and PBC treatment seladelpar could see combined annual sales of $3.7 billion by 2030, according to Raymond James' model. Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “m ...

Biotech giant Gilead Sciences, Inc. (GILD) , a leader in HIV drugs, is having a tough run as recent pipeline setbacks disappointed investors and acquisition-related charges adversely impacted the bottom line. The stock has been under pressure owing to these challenges.While the company’s leading HIV franchise maintains momentum and its efforts to build an oncology franchise to diversify its portfolio are encouraging, the failure of late-stage studies evaluating oncology drug Trodelvy (sacituzumab govitecan) ...

Shares of drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) are up 2% in pre-market trading, after Raymond James upgraded the stock to "outperform" from "market perform."  According to the the brokerage, GILD -- one of Schaeffer's top 2024 picks -- has support over the next five years from two key drug candidates that could increase revenue growth.Overall, analysts are pessimistic towards toward the security, with 14 of 24 covering firms recommending a "hold," and the stock's average 12-month price target stand ...

Gilead Sciences, Foster City, CA Tomsmith585/iStock Unreleased via Getty ImagesGilead Sciences (NASDAQ:GILD) on Thursday announced positive topline results from an interim analysis of its Phase III PURPOSE 1 trial. The trial which tested the efficacy of twice-yearly lenacapavir versus once daily Truvada and Descovy in approximately 5,300 women at risk of contracting HIV in South Africa and Uganda, found 0 incident cases of HIV infection in the lenacapavir group. In other words, among the 2,124 treated wit ...

Gilead Sciences, Inc. (GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1.PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety and efficacy of twice-yearly, subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) and once-daily oral Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF) in more than 5,300 cisgender women and adolescent girls aged 16-25 years across 25 sites in South Africa and three sites in Uganda.B ...

Gilead Sciences NASDAQ: GILD saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. The biopharmaceutical company revealed 100% efficacy in its Phase 3 HIV prevention trial, marking the first trial showing zero infections. Given the stock's underperformance this year, this news is a significant relief for investors. Let's delve into the trial's details, the stock's recent performance, and its future prospects.Get Gilead Sciences alerts:Gilead's Lenacapa ...

Gilead Sciences (GILD) shares soared 8.5% in the last trading session to close at $68.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.The surge is mostly attributable to positive results from the late study PURPOSE 1 wherein twice-yearly lenacapavir demonstrated its potential as a new tool to help prevent HIV infections with zero infections and 100% efficacy.  On the basis of these results, ...

Key TakeawaysA Phase 3 trial of Gilead's injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women. Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants.More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval.Shares of Gilead surged Thursday following the news. Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announ ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Both GILD and JAZZ are lower in 2024 and way off their record highs from 2015Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level. Amidst this choppiness, two pharmaceutical stocks are worth a closer look today; Gilead Sciences, Inc. (NASDAQ:GILD) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ).GILD is up 9.% to trade at $69.10, on track for its biggest single-session pop since Oct. 2022. The pharma giant repo ...